Compare BOLT & AMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOLT | AMS |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 11.1M |
| IPO Year | 2021 | 1995 |
| Metric | BOLT | AMS |
|---|---|---|
| Price | $3.28 | $1.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | ★ 21.3K | 15.0K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,695,000.00 | ★ $19,714,000.00 |
| Revenue This Year | N/A | $6.93 |
| Revenue Next Year | $133.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.07 | ★ 0.81 |
| 52 Week Low | $3.13 | $1.25 |
| 52 Week High | $7.20 | $3.11 |
| Indicator | BOLT | AMS |
|---|---|---|
| Relative Strength Index (RSI) | 34.35 | 49.89 |
| Support Level | N/A | $1.37 |
| Resistance Level | $4.46 | $1.75 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 20.59 | 27.78 |
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. Company operates in two segments, the medical equipment leasing segment where a contract exists between the hospital and the Company and the direct patient services segment, where a contract exists between the Company facilities and the individual treated at the facility. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates it's key revenue from the domestic market.